EPISODE · Mar 25, 2022 · 10 MIN
MPR Weekly Dose 111 - Allergy Spray OTC Switch; Syringe Malfunction Prompts Recall; Sciatica Pain Tx Update; FDA Alert for COVID-19 Tests; Resubmitted Teplizumab Application Accepted
from MPR Weekly Dose
Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.
Embed this episode
Ready to play
MPR Weekly Dose 111 - Allergy Spray OTC Switch; Syringe Malfunction Prompts Recall; Sciatica Pain Tx Update; FDA Alert for COVID-19 Tests; Resubmitted Teplizumab Application Accepted
0:00
10:56
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 10 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on March 25, 2022.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!